195 related articles for article (PubMed ID: 24464810)
1. Neurofilament Heavy polypeptide CpG island methylation associates with prognosis of renal cell carcinoma and prediction of antivascular endothelial growth factor therapy response.
Dubrowinskaja N; Gebauer K; Peters I; Hennenlotter J; Abbas M; Scherer R; Tezval H; Merseburger AS; Stenzl A; Grünwald V; Kuczyk MA; Serth J
Cancer Med; 2014 Apr; 3(2):300-9. PubMed ID: 24464810
[TBL] [Abstract][Full Text] [Related]
2. GATA5 CpG island methylation in renal cell cancer: a potential biomarker for metastasis and disease progression.
Peters I; Eggers H; Atschekzei F; Hennenlotter J; Waalkes S; Tränkenschuh W; Grosshennig A; Merseburger AS; Stenzl A; Kuczyk MA; Serth J
BJU Int; 2012 Jul; 110(2 Pt 2):E144-52. PubMed ID: 22289415
[TBL] [Abstract][Full Text] [Related]
3. Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma.
Breault JE; Shiina H; Igawa M; Ribeiro-Filho LA; Deguchi M; Enokida H; Urakami S; Terashima M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):557-64. PubMed ID: 15701841
[TBL] [Abstract][Full Text] [Related]
4. Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma.
Gebauer K; Peters I; Dubrowinskaja N; Hennenlotter J; Abbas M; Scherer R; Tezval H; Merseburger AS; Stenzl A; Kuczyk MA; Serth J
Br J Cancer; 2013 Jan; 108(1):131-8. PubMed ID: 23321515
[TBL] [Abstract][Full Text] [Related]
5. DNA methylation biomarkers predict progression-free and overall survival of metastatic renal cell cancer (mRCC) treated with antiangiogenic therapies.
Peters I; Dubrowinskaja N; Abbas M; Seidel C; Kogosov M; Scherer R; Gebauer K; Merseburger AS; Kuczyk MA; Grünwald V; Serth J
PLoS One; 2014; 9(3):e91440. PubMed ID: 24633192
[TBL] [Abstract][Full Text] [Related]
6. Methylation of PCDH17 and NEFH as prognostic biomarker for nonmetastatic RCC: A cohort study.
Koudonas A; Papaioannou M; Kampantais S; Anastasiadis A; Hatzimouratidis K; Dimitriadis G
Medicine (Baltimore); 2022 Jul; 101(28):e29599. PubMed ID: 35838992
[TBL] [Abstract][Full Text] [Related]
7. GATA5 CpG island hypermethylation is an independent predictor for poor clinical outcome in renal cell carcinoma.
Peters I; Gebauer K; Dubrowinskaja N; Atschekzei F; Kramer MW; Hennenlotter J; Tezval H; Abbas M; Scherer R; Merseburger AS; Stenzl A; Kuczyk MA; Serth J
Oncol Rep; 2014 Apr; 31(4):1523-30. PubMed ID: 24549248
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and diagnostic relevance of hypermethylated in cancer 1 (HIC1) CpG island methylation in renal cell carcinoma.
Eggers H; Steffens S; Grosshennig A; Becker JU; Hennenlotter J; Stenzl A; Merseburger AS; Kuczyk MA; Serth J
Int J Oncol; 2012 May; 40(5):1650-8. PubMed ID: 22327210
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation of neural EGFL like 1 (NELL1) is associated with advanced disease and the metastatic state of renal cell cancer patients.
Peters I; Dubrowinskaja N; Hennenlotter J; Antonopoulos WI; Von Klot CAJ; Tezval H; Stenzl A; Kuczyk MA; Serth J
Oncol Rep; 2018 Dec; 40(6):3861-3868. PubMed ID: 30272321
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of promoter CpG island methylation of obesity-related genes in patients with nonmetastatic renal cell carcinoma.
Mendoza-Pérez J; Gu J; Herrera LA; Tannir NM; Zhang S; Matin S; Karam JA; Wood CG; Wu X
Cancer; 2017 Sep; 123(18):3617-3627. PubMed ID: 28543182
[TBL] [Abstract][Full Text] [Related]
11. A Four-Gene Promoter Methylation Marker Panel Consisting of
van Vlodrop IJH; Joosten SC; De Meyer T; Smits KM; Van Neste L; Melotte V; Baldewijns MMLL; Schouten LJ; van den Brandt PA; Jeschke J; Yi JM; Schuebel KE; Ahuja N; Herman JG; Aarts MJ; Bosman FT; Van Criekinge W; van Engeland M
Clin Cancer Res; 2017 Apr; 23(8):2006-2018. PubMed ID: 27756787
[No Abstract] [Full Text] [Related]
12. Development of a prognostic risk model for clear cell renal cell carcinoma by systematic evaluation of DNA methylation markers.
Joosten SC; Odeh SNO; Koch A; Buekers N; Aarts MJB; Baldewijns MMLL; Van Neste L; van Kuijk S; Schouten LJ; van den Brandt PA; Tjan-Heijnen VC; van Engeland M; Smits KM
Clin Epigenetics; 2021 May; 13(1):103. PubMed ID: 33947447
[TBL] [Abstract][Full Text] [Related]
13. Prognostic DNA methylation markers for renal cell carcinoma: a systematic review.
Joosten SC; Deckers IA; Aarts MJ; Hoeben A; van Roermund JG; Smits KM; Melotte V; van Engeland M; Tjan-Heijnen VC
Epigenomics; 2017 Sep; 9(9):1243-1257. PubMed ID: 28803494
[TBL] [Abstract][Full Text] [Related]
14. CpG dinucleotide-specific hypermethylation of the TNS3 gene promoter in human renal cell carcinoma.
Carter JA; Górecki DC; Mein CA; Ljungberg B; Hafizi S
Epigenetics; 2013 Jul; 8(7):739-47. PubMed ID: 23803643
[TBL] [Abstract][Full Text] [Related]
15. [Two CpG-islands of SEMA3B gene: methylation in clear cell renal cell carcinoma].
Loginov VI; Khodyrev DS; Pronina IV; Maliukova AV; Kazubskaia TP; Ermilova VD; Gar'kavtseva RF; Zabarovskiĭ ER; Braga EA
Mol Biol (Mosk); 2009; 43(6):1088-92. PubMed ID: 20088387
[TBL] [Abstract][Full Text] [Related]
16. SFRP1 CpG island methylation locus is associated with renal cell cancer susceptibility and disease recurrence.
Atschekzei F; Hennenlotter J; Jänisch S; Großhennig A; Tränkenschuh W; Waalkes S; Peters I; Dörk T; Merseburger AS; Stenzl A; Kuczyk MA; Serth J
Epigenetics; 2012 May; 7(5):447-57. PubMed ID: 22419128
[TBL] [Abstract][Full Text] [Related]
17. Myopodin methylation is a prognostic biomarker and predicts antiangiogenic response in advanced kidney cancer.
Pompas-Veganzones N; Sandonis V; Perez-Lanzac A; Beltran M; Beardo P; Juárez A; Vazquez F; Cozar JM; Alvarez-Ossorio JL; Sanchez-Carbayo M
Tumour Biol; 2016 Oct; 37(10):14301-14310. PubMed ID: 27592258
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma.
Revill K; Wang T; Lachenmayer A; Kojima K; Harrington A; Li J; Hoshida Y; Llovet JM; Powers S
Gastroenterology; 2013 Dec; 145(6):1424-35.e1-25. PubMed ID: 24012984
[TBL] [Abstract][Full Text] [Related]
19. DNA methylation of tumor associated calcium signal transducer 2 (TACSTD2) loci shows association with clinically aggressive renal cell cancers.
Katzendorn O; Peters I; Dubrowinskaja N; Tezval H; Tabrizi PF; von Klot CA; Hennenlotter J; Lafos M; Kuczyk MA; Serth J
BMC Cancer; 2021 Apr; 21(1):444. PubMed ID: 33882870
[TBL] [Abstract][Full Text] [Related]
20. Methylation-associated silencing of TU3A in human cancers.
Awakura Y; Nakamura E; Ito N; Kamoto T; Ogawa O
Int J Oncol; 2008 Oct; 33(4):893-9. PubMed ID: 18813805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
